Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• "Moderate Buy" consensus from nine analysts (1 sell, 1 hold, 6 buy, 1 strong buy) with an average 12‑month target price of $21.63.
• The stock opened at $5.72 with a market cap of about $549M and a negative PE; Compass reported an EPS miss last quarter of ($1.00) vs. estimates of ($0.41), and analysts forecast -2.33 EPS for the fiscal year.
• Analyst views are mixed and variable — notable revisions include HC Wainwright raising its target from $40 to $70, RBC to $22, while Morgan Stanley and Canaccord trimmed targets to $16 and $18 respectively, reflecting divergent expectations for upside.

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $21.6250.

A number of research firms have weighed in on CMPS. Royal Bank Of Canada upped their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. Lifesci Capital upgraded shares of Compass Pathways to a "strong-buy" rating in a research report on Thursday, February 12th. HC Wainwright upped their price objective on shares of Compass Pathways from $40.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Morgan Stanley reduced their target price on shares of Compass Pathways from $18.00 to $16.00 and set an "overweight" rating for the company in a research report on Wednesday, March 25th. Finally, Canaccord Genuity Group decreased their price target on shares of Compass Pathways from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, March 26th.

Compass Pathways Stock Performance

NASDAQ:CMPS opened at $5.72 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.77 and a current ratio of 0.77. The company has a fifty day moving average of $6.43 and a two-hundred day moving average of $6.33. The stock has a market capitalization of $549.23 million, a PE ratio of -1.85 and a beta of 2.01. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.90.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.59). As a group, research analysts forecast that Compass Pathways will post -2.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

Several hedge funds and other institutional investors have recently modified their holdings of CMPS. Toronto Dominion Bank lifted its stake in shares of Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company's stock worth $17,447,000 after buying an additional 1,529,013 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Compass Pathways in the third quarter worth about $7,890,000. Nantahala Capital Management LLC lifted its stake in shares of Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company's stock worth $11,704,000 after buying an additional 1,350,698 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in shares of Compass Pathways in the third quarter worth about $6,926,000. Finally, Siren L.L.C. purchased a new position in shares of Compass Pathways in the fourth quarter worth about $6,900,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.